Literature DB >> 36258707

Immunocompetent Patient With Primary Bone Marrow Hodgkin Lymphoma.

Armaan Dhaliwal1, Vanessa F Eller2, Jeffrey J Pu1,2.   

Abstract

Hodgkin lymphoma (HL) is a hematologic malignancy that comprises about 10% of all lymphomas with the most common type being classical HL (cHL). The typical clinical presentation of cHL involves multiple region lymphadenopathy and a chest mass found on imaging. However, not all patients present with the typical symptomology of cHL which poses a diagnostic challenge. Extranodal HL, especially primary bone marrow HL (PBMHL), has been described in immunocompromised patients with human immunodeficiency virus (HIV). In this case report, we present a PBMHL case in an immunocompetent patient with no HIV exposure. We discuss a 51-year-old immunocompetent female who presented with 2 - 3 months of fever, confusion, generalized myalgias, and fatigue. She had no lymphadenopathy on physical exam. On further testing, the patient's blood work demonstrated cytopenia and imaging confirmed no lymphadenopathy. Eventually, a bone marrow evaluation established her diagnosis of PBMHL. The patient expired after receiving one cycle of a modified chemotherapy regimen. This case illustrates that HL can be associated with an atypical clinical presentation which may delay diagnosis and treatment. PBMHL can occur in the normal population who is not immunocompromised nor HIV positive. In this situation, the best diagnostic approach is a thorough medical history, physical exam, and bone marrow aspiration and biopsy. Presence of constitutional symptoms without any lymphadenopathy or chest mass should raise the concern for possible atypical HL such as PBMHL. Accurate and timely identification of PBMHL allows for timely initiation of appropriate therapy. While cHL is responsive to chemotherapy, further research is required to improve the therapy for PBMHL. Copyright 2022, Dhaliwal et al.

Entities:  

Keywords:  Atypical Hodgkin lymphoma; HIV; Hodgkin lymphoma; Primary bone marrow Hodgkin lymphoma

Year:  2022        PMID: 36258707      PMCID: PMC9534194          DOI: 10.14740/jmc3973

Source DB:  PubMed          Journal:  J Med Cases        ISSN: 1923-4155


  13 in total

Review 1.  HIV-associated primary bone marrow Hodgkin's lymphoma: a distinct entity?

Authors:  Binay K Shah; Seshan Subramaniam; David Peace; Carlos Garcia
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

2.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

3.  Neoplastic cells of Hodgkin's disease show differences in EBV expression between Kenya and Italy.

Authors:  L Leoncini; D Spina; A Nyong'o; O Abinya; C Minacci; A Disanto; F De Luca; A De Vivo; E Sabattini; S Poggi; S Pileri; P Tosi
Journal:  Int J Cancer       Date:  1996-03-15       Impact factor: 7.396

4.  Isolated bone marrow manifestation of HIV-associated Hodgkin lymphoma.

Authors:  Maurilio Ponzoni; Luca Fumagalli; Giuseppe Rossi; Massimo Freschi; Alessandro Re; Maria Grazia Viganò; Massimo Guidoboni; Riccardo Dolcetti; Robert W McKenna; Fabio Facchetti
Journal:  Mod Pathol       Date:  2002-12       Impact factor: 7.842

5.  HIV-negative Primary Bone Marrow Hodgkin Lymphoma Manifesting with a High Fever Associated with Hemophagocytosis as the Initial Symptom: A Case Report and Review of the Previous Literature.

Authors:  Yasuyoshi Morita; Masakatsu Emoto; Kentaro Serizawa; Shinya Rai; Chikara Hirase; Yoshitaka Kanai; Yasuyo Ohyama; Toshihiko Shiga; Hirokazu Tanaka; Junichi Miyatake; Yoichi Tatsumi; Takashi Ashida; Masatomo Kimura; Masafumi Ito; Itaru Matsumura
Journal:  Intern Med       Date:  2015-06-01       Impact factor: 1.271

6.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.

Authors:  G Bonadonna; R Zucali; S Monfardini; M De Lena; C Uslenghi
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

7.  Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma.

Authors:  A Kolstad; O Nome; J Delabie; G F Lauritzsen; A Fossa; H Holte
Journal:  Leuk Lymphoma       Date:  2007-03

8.  Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis.

Authors:  P M Mauch; L A Kalish; M Kadin; C N Coleman; R Osteen; S Hellman
Journal:  Cancer       Date:  1993-03-15       Impact factor: 6.860

9.  Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Authors:  Andreas Engert; Volker Diehl; Jeremy Franklin; Andreas Lohri; Bernd Dörken; Wolf-Dieter Ludwig; Peter Koch; Mathias Hänel; Michael Pfreundschuh; Martin Wilhelm; Lorenz Trümper; Walter-Erich Aulitzky; Martin Bentz; Mathias Rummel; Orhan Sezer; Hans-Konrad Müller-Hermelink; Dirk Hasenclever; Markus Löffler
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

10.  Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.

Authors:  David J Straus; Monika Długosz-Danecka; Joseph M Connors; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Radhakrishnan Ramchandren; Pier Luigi Zinzani; Martin Hutchings; Javier Munoz; Hun Ju Lee; Won Seog Kim; Ranjana Advani; Stephen M Ansell; Anas Younes; Andrea Gallamini; Rachael Liu; Meredith Little; Keenan Fenton; Michelle Fanale; John Radford
Journal:  Lancet Haematol       Date:  2021-06       Impact factor: 18.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.